Evaluate the results of recent clinical trials using novel therapeutic agents for the treatment of gastrointestinal malignancies.
Assess the efficacy and safety of the addition of antiangiogenic agents when added to standard chemotherapy regimens, and consider the survival benefits the addition of these agents may provide your appropriate patients with colorectal cancer.
Understand the rationale for using anti–epidermal growth factor receptor (EGFR) agents as single-agent treatments, or as added components to cytotoxic chemotherapy regimens, and the potential survival benefits the addition of an anti-EGFR agent may confer on your patients with gastrointestinal cancer.
Explain how a genetic profile could aid in prospectively identifying the optimal chemotherapy treatment for your patients with colorectal cancer.
Recognize signs and symptoms of the common toxicities associated with targeted agents currently used in the treatment of colorectal cancer and evaluate the best methods to manage them.
Who Should Attend: Physicians, Nurses, and othe Health-Care Professionals
Registration Information: Please see website for further information.
Conference Fees: Please see website for further information
Nov 26, 2012 - For patients with metastatic colorectal cancer or gastrointestinal stromal tumors who have progressed in spite of treatment, the multikinase inhibitor regorafenib may improve survival, according to the results of two phase 3 studies published online Nov. 22 in The Lancet.